Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Medical care, Cost of - United States. --- Medicare. --- Clinical trials --- Medical care, Cost of --- Medicare --- Health insurance --- Older people --- Medicaid --- Medigap --- Medical care

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Health care costs represent a nearly 18% of U.S. gross domestic product and 20% of government spending. While there is detailed information on where these health care dollars are spent, there is much less evidence on how this spending affects health. The research in Measuring and Modeling Health Care Costs seeks to connect our knowledge of expenditures with what we are able to measure of results, probing questions of methodology, changes in the pharmaceutical industry, and the shifting landscape of physician practice. The research in this volume investigates, for example, obesity's effect on health care spending, the effect of generic pharmaceutical releases on the market, and the disparity between disease-based and population-based spending measures. This vast and varied volume applies a range of economic tools to the analysis of health care and health outcomes. Practical and descriptive, this new volume in the Studies in Income and Wealth series is full of insights relevant to health policy students and specialists alike.

Medical care, Cost of --- Medical care --- Cost of medical care --- Health care costs --- Health care expenditures --- Medical costs --- Medical expenses --- Medical service, Cost of --- Medicine --- Medical economics --- Medical savings accounts --- Measurement. --- Cost control. --- Costs --- Medical care, Cost of - United States - Measurement --- Medical care - United States - Cost control --- Health Care Costs --- Models, Theoretical --- United States --- health costs. --- health outcomes. --- market design. --- pharmaceuticals.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

"Interim Report of the Committee on Geographic Variation in Health Care Spending and Promotion of High-Value Health Care: Preliminary Committee Observations is designed to provide the committee's preliminary observations for the 113th Congress as it considers further Medicare reform. This report contains only key preliminary observations related primarily to the committee's commissioned analyses of Medicare Parts A (Hospital Insurance program), B (Supplementary Medical Insurance program) and D (outpatient prescription drug benefit), complemented by other empirical investigations. It does not contain any observations related to the committee's commissioned analyses of the commercial insurer population, Medicare Advantage, or Medicaid, which will be presented in the committee's final report after completion of quality-control activities. This interim report excludes conclusions or recommendations related to the committee's consideration of the geographic value index or other payment reforms designed to promote high value care. Additional analyses are forthcoming, which will influence the committee's deliberations. These analyses include an exploration of how Medicare Part C (Medicare Advantage) and commercial spending, utilization, and quality vary compared with, and possibly are influenced by, Medicare Parts A and B spending, utilization, and quality. The committee also is assessing potential biases that may be inherent to Medicare and commercial claims-based measures of health status. Based on this new evidence and continued review of the literature, the committee will confirm the accuracy of the observations presented in this interim report and develop final conclusions and recommendations, which will be published in the committee's final report"--Publisher's description.

Health care reform -- United States. --- Medical care, Cost of -- United States. --- Medicare -- Finance. --- Medicare -- Statistics. --- Medicare --- Medical care, Cost of --- Health care reform --- Legislation as Topic --- Health Care Quality, Access, and Evaluation --- Delivery of Health Care --- Costs and Cost Analysis --- Medical Assistance --- Health Services Administration --- Insurance, Health --- Earth Sciences --- Health Care --- Insurance --- Natural Science Disciplines --- Patient Care Management --- Social Control, Formal --- Economics --- Public Assistance --- Health Care Economics and Organizations --- Financing, Organized --- Financing, Government --- Disciplines and Occupations --- Health Services Accessibility --- Quality of Health Care --- Health Expenditures --- Geography --- Public Health --- Health & Biological Sciences --- Medical Care Plans --- Statistics --- Finance --- Finance.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Technological innovation is deeply woven into the fabric of American culture, and is no less a basic feature of American health care. Medical technology saves lives and relieves suffering, and is enormously popular with the public, profitable for doctors, and a source of great wealth for industry. Yet its costs are rising at a dangerously unsustainable rate. The control of technology costs poses a terrible ethical and policy dilemma. How can we deny people what they may need to live and flourish? Yet is it not also harmful to let rising costs strangle our health care system, eventually harming everyone?In Taming the Beloved Beast, esteemed medical ethicist Daniel Callahan confronts this dilemma head-on. He argues that we can't escape it by organizational changes alone. Nothing less than a fundamental transformation of our thinking about health care is needed to achieve lasting and economically sustainable reform. The technology bubble, he contends, is beginning to burst.Callahan weighs the ethical arguments for and against limiting the use of medical technologies, and he argues that reining in health care costs requires us to change entrenched values about progress and technological innovation. Taming the Beloved Beast shows that the cost crisis is as great as that of the uninsured. Only a government-regulated universal health care system can offer the hope of managing technology and making it affordable for all.

Medical care, Cost of --United States. --- Medical technology --Economic aspects --United States. --- Medical care, Cost of --- Medical technology --- Health Care Costs --- Biomedical Technology --- United States --- Economics --- Insurance --- Delivery of Health Care --- Technology --- North America --- Costs and Cost Analysis --- Financing, Organized --- Social Sciences --- Americas --- Health Care Quality, Access, and Evaluation --- Anthropology, Education, Sociology and Social Phenomena --- Technology, Industry, and Agriculture --- Geographic Locations --- Health Care Economics and Organizations --- Technology, Industry, Agriculture --- Health Care --- Geographicals --- Medical Economics --- Public Health --- Health & Biological Sciences --- Economic aspects --- Health care technology --- Health technology --- Biomedical Technologies --- Technology, Biomedical --- Technology, Health --- Technology, Health Care --- Health Care Technology --- Health Technology --- Biomedical Engineering --- Medical Informatics --- Costs, Medical Care --- Health Costs --- Healthcare Costs --- Medical Care Costs --- Treatment Costs --- Cost, Health --- Cost, Health Care --- Cost, Healthcare --- Cost, Medical Care --- Cost, Treatment --- Costs, Health --- Costs, Health Care --- Costs, Healthcare --- Costs, Treatment --- Health Care Cost --- Health Cost --- Healthcare Cost --- Medical Care Cost --- Treatment Cost --- Health Expenditures --- Indemnity --- Insurance Premiums --- Insurance Premium --- Premium, Insurance --- Premiums, Insurance --- economics --- E-books --- Cost of medical care --- Health care costs --- Health care expenditures --- Medical care --- Medical costs --- Medical expenses --- Medical service, Cost of --- Medicine --- Medical economics --- Medical savings accounts --- Assurance (Insurance) --- Coverage, Insurance --- Indemnity insurance --- Insurance coverage --- Insurance industry --- Insurance protection --- Mutual insurance --- Underwriting --- Finance --- Costs --- Ethics --- Technology Assessment, Biomedical --- W 82 Biomedical technology (General)